Mohamad Mohty
Professor of Hematology and past-president of the European society for Blood and Marrrow Transplantation (EBMT)
Last synced from Twitter 16m ago
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only... The post Induction therapy in myeloma: an ever-changing paradigm appeared first on VJHemOnc.
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only...
The latest from the StarTribune
Follow the StarTribune for the news, photos and videos from the Twin Cities and beyond.
Mohamad Mohty
How a doctor from a tiny island rose to be Mayo's new CEO - StarTribune.com startribune.com/how-a-doctor-f…
41h
How a doctor from a tiny Mediterranean island rose to be Mayo Clinic’s new CEO
As health care and technology merge, new chief leads a venerable institution through an industry's crossroads.
Mohamad Mohty
How a doctor from a tiny island rose to be Mayo's new CEO - StarTribune.com startribune.com/how-a-doctor-f…
41h
Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation
Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation
New Guidelines for Statistical Reporting in the Journal | NEJM
Editorial from The New England Journal of Medicine — New Guidelines for Statistical Reporting in the Journal
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
The results from this unplanned, FDA-requested, interim analysis showed that the benefit–risk
profile of pembrolizumab plus lenalidomide and dexamethasone is unfavourable for patients
with newly diagnosed, previously untreated multiple myeloma....
2
Mohamad Mohty
« the benefit–risk profile of pembrolizumab plus lenalidomide and dexamethasone is unfavourable for patients with newly diagnosed, previously untreated multiple myeloma. » (KEYNOTE-185)
@szusmani @SagarLonialMD @VincentRK
4d
The Untold Story of the Longest Persisting CAR-T Cells in CLL
A deep dive into how CAR-T cells evolved in 2 patients with chronic lymphocytic leukemia who have had the longest complete remissions to date.
The case for IMiDs in relapsed MM
Meral Beksac, MD, from Ankara University, Ankara, Turkey, discusses the case for using immunomodulatory drugs (IMiDs) in the treatment of relapsed multiple m...
The Promise and Price of Cellular Therapies
New “living drugs”—made from a patient’s own cells—can cure once incurable cancers, Siddhartha Mukherjee writes. But can we afford them?
Mohamad Mohty
« Procedures come alive in the tinkering, fussing hands of their operators, who navigate seemingly insurmountable challenges: the bone-marrow transplanter who countenances 83 deaths before mastering the method, the surgeon who figures out how best to... »
6d
Direct adjusted survival and cumulative incidence curves for observational studies
Direct adjusted survival and cumulative incidence curves for observational studies
Les CAR-T cells à l’ASCO 2019
- Avancement des CAR-T cells en hématologie : Pr Jason Westin (Houston, USA)- Futur des CAR-T cells en hématologie : Pr Jason Westin (Houston, USA)- Condition des progrès des CAR-T cells en oncologie : Pr Jason Westin (Houston, USA)
Avec le Pr...
IACH Meeting Paris 2019: Meet the Speakers
1
Mohamad Mohty
IACH Meeting Paris 2019: Meet the Speakers
Last few days for free or reduced registration
@TheIACH
7d
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma - Multiple Myeloma, On Location, Other Meetings - ASH Clinical News
2
Mohamad Mohty
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma - ASH Clinical News
@ASH_hematology @SagarLonialMD @MyelomaTeacher @af3m_myelome
8d
FDA Declines to Approve Quizartinib for FLT3-Mutated Acute Myeloid Leukemia
FDA Declines to Approve Quizartinib for FLT3-Mutated Acute Myeloid Leukemia - Acute Leukemias, Online Exclusives - ASH Clinical News
1
Mohamad Mohty
FDA Declines to Approve Quizartinib for FLT3-Mutated Acute Myeloid Leukemia - ASH Clinical News @ASH_hematology
8d
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI
The impact of the use of antithymocyte globulin (ATG) following a total body irradiation (TBI)–based myeloablative conditioning regimen has been poorly explored. We retrospectively analyzed 724 patients who underwent a first allogeneic hematopoietic...
1
Mohamad Mohty
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI | Blood Advances
@TheEBMT @ASH_hematology
7d
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. - PubMed - NCBI
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.